{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Large+portion&page=9", "query": { "intervention": "Large portion", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 205, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Large+portion&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Large+portion&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T15:15:08.304Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02061761", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "BMS-986016", "type": "BIOLOGICAL" }, { "name": "BMS-936558", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-03-13", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 8, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061761" }, { "nct_id": "NCT03255096", "title": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "High-Grade B-cell Lymphoma" ], "interventions": [ { "name": "RO6870810", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-08-28", "completion_date": "2019-07-03", "has_results": false, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 4, "location_summary": "Duarte, California • Stanford, California • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03255096" }, { "nct_id": "NCT00712582", "title": "Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Etoposide, carboplatin, ifosfamide", "type": "DRUG" }, { "name": "Rituximab, Ifosfamide, Etoposide, Carboplatin", "type": "DRUG" }, { "name": "Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 96, "start_date": "2008-07-01", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00712582" }, { "nct_id": "NCT05565417", "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Cutaneous Squamous Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Small Bowel Cancer", "Esophageal Cancer", "Colorectal Cancer", "Diffuse Large B Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "IMT-009", "type": "DRUG" }, { "name": "Fruquintinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Immunitas Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2022-11-28", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 9, "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565417" }, { "nct_id": "NCT03527810", "title": "Hiatal Interrogation in Sleeve Gastrectomy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleeve Gastrectomy" ], "interventions": [ { "name": "Sleeve Gastrectomy Without Interrogation of Hiatus", "type": "PROCEDURE" }, { "name": "Sleeve Gastrectomy With Interrogation of Hiatus", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Miguel Burch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-09-04", "completion_date": "2022-03-07", "has_results": false, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03527810" }, { "nct_id": "NCT04277637", "title": "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Malignancies" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2020-03-24", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 13, "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04277637" }, { "nct_id": "NCT05155891", "title": "Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Benign Prostatic Hyperplasia" ], "interventions": [ { "name": "Embosphere Microspheres", "type": "DEVICE" }, { "name": "HoLEP Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "MALE", "summary": "50 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2022-06-17", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05155891" }, { "nct_id": "NCT02883985", "title": "Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "6 Gy/ fraction", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2000-05", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2018-12-21", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02883985" }, { "nct_id": "NCT04384484", "title": "Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Loncastuximab Tesirine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2020-09-16", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 11, "location_summary": "La Jolla, California • Redlands, California • Whittier, California + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04384484" }, { "nct_id": "NCT05152693", "title": "Effects of Variety and Portion Size on Meal Intake of Adults", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eating Behavior" ], "interventions": [ { "name": "Low variety", "type": "OTHER" }, { "name": "High Variety", "type": "OTHER" }, { "name": "Small Portion Size", "type": "OTHER" }, { "name": "Large Portion Size", "type": "OTHER" }, { "name": "With Beverage", "type": "OTHER" }, { "name": "Without Beverage", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Penn State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "20 Years to 65 Years · Female only" }, "enrollment_count": 0, "start_date": "2022-01-20", "completion_date": "2023-01-27", "has_results": false, "last_update_posted_date": "2021-12-10", "last_synced_at": "2026-10-20T15:15:08.304Z", "location_count": 1, "location_summary": "University Park, Pennsylvania", "locations": [ { "city": "University Park", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05152693" } ] }